tations and estimates. We may not
actually achieve these plans, intentions or expectations and Renovis
cautions investors not to place undue reliance on our forward-looking
statements. Actual results or events could differ materially from the
plans, intentions and expectations disclosed in the forward-looking
statements we make. Various important factors that could cause actual
results or events to differ materially from these forward-looking
statements include, but are not limited to, the risk that the conditions
relating to the required regulatory clearance of the transaction might not
be satisfied in a timely manner or at all, risks relating to the
integration of the technologies and businesses of Evotec and Renovis,
unanticipated expenditures, changing relationships with customers,
suppliers and strategic partners, and other factors that are described in
greater detail in the reports we file with the Securities and Exchange
Commission, including the "Risk Factors" section of our Quarterly Report on
Form 10-Q, which was filed with the Securities and Exchange Commission on
August 8, 2007, and our Annual Report on Form 10-K, which was filed on
March 15, 2007. Renovis is providing this information as of the date of
this press release and does not undertake any obligation to update any
forward-looking statements as a result of new information, future events or
otherwise.
Additional information about the transaction
Renovis filed a Current Report on Form 8-K with the Securities and
Exchange Commission on September 24, 2007, that includes as an exhibit the
Agreement and Plan of Merger between Evotec and Renovis. Evotec intends to
file a Registration Statement on Form F-4 with the Securities and Exchange
Commission in connection with the proposed merger. Evotec and Renovis
expect to mail a joint proxy statement/prospectus, which will form part of
the Registration Statement on Form F-4, to stockholders of Renovis in
connection with the proposed merger. This d
'/>"/>
SOURCE Renovis, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 Related biology technology :1.
Renovis to Present at CIBC World Markets Healthcare Conference2.
EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound3.
QMed, Inc. Reports July Medicare SNP Enrollments4.
Phlo Affiliate Reports Expanded Coverage to Oregon Border5.
Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results6.
Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 20077.
Carrington Reports Second Quarter 2007 Results8.
Avitar Reports Third Quarter Financial Results for Fiscal 20079.
Response Genetics Reports Second Quarter 2007 Financial Results10.
Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results11.
Transgenomic, Inc. Reports Second Quarter 2007 Results